Coronary MR angiography using citrate-coated very small superparamagnetic iron oxide particles as blood-pool contrast agent: Initial experience in humans

Journal of Magnetic Resonance Imaging

Volumn 34, Issue 4, 2011, Pages 816-823

  Wagner, Moritz ^a   Wagner, Susanne ^a   Schnorr, Jörg ^a   Schellenberger, Eyk ^a   Kivelitz, Dietmar ^b   Krug, Lasse ^a   Dewey, Marc ^a   Laule, Michael ^a   Hamm, Bernd ^a   Taupitz, Matthias ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Asklepios Klinik St Gerog   (Germany)

Author keywords

angiography; blood pool; contrast agent; coronary artery disease; magnetic resonance

Indexed keywords

SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; VSOPC 184;

ADULT; ARTICLE; CLINICAL ARTICLE; COLD SENSATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DIAGNOSTIC TEST ACCURACY STUDY; DIZZINESS; DRUG INDUCED HEADACHE; FEMALE; HAND DISEASE; HAND TENSION; HEAT SENSATION; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; MALAISE; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SWEATING; TONGUE DISEASE;

ADULT; AGED; CASE-CONTROL STUDIES; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; DEXTRANS; FEMALE; FERUMOXYTOL; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETITE NANOPARTICLES; MALE; MIDDLE AGED; RADIOGRAPHIC IMAGE ENHANCEMENT; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SIGNAL-TO-NOISE RATIO;

EID: 80053038307     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.22683     Document Type: Article

References (34)

1. Prompona M, Cyran C, Nikolaou K, et al. Contrast-enhanced whole-heart MR coronary angiography at 3.0 T using the intravascular contrast agent gadofosveset. Invest Radiol 2009; 44: 369-374.
2. Stuber M, Botnar RM, Danias PG, et al. Contrast agent-enhanced, free-breathing, three-dimensional coronary magnetic resonance angiography. J Magn Reson Imaging 1999; 10: 790-799. (Pubitemid 29519783)
3. Wagner M, Rosler R, Lembcke A, et al. Whole-heart coronary magnetic resonance angiography at 1.5 tesla: does a blood-pool contrast agent improve diagnostic accuracy? Invest Radiol 2011; 46: 152-159.
4. Herborn CU, Barkhausen J, Paetsch I, et al. Coronary arteries: contrast-enhanced MR imaging with SH L 643A-experience in 12 volunteers. Radiology 2003; 229: 217-223. (Pubitemid 37152127)
5. Herborn CU, Schmidt M, Bruder O, Nagel E, Shamsi K, Barkhausen J,. MR coronary angiography with SH L 643 A: initial experience in patients with coronary artery disease. Radiology 2004; 233: 567-573. (Pubitemid 39423819)
6. Bunce NH, Keegan J, Gatehouse PD, et al. Initial experience with the intravascular contrast agent NC100150-injection (Clariscan) for breath-hold and navigator-gated magnetic resonance coronary artery imaging. J Magn Reson Imaging 2002; 16: 217-223. (Pubitemid 34810061)
7. Klein C, Schalla S, Schnackenburg B, et al. Improvement of image quality of non-invasive coronary artery imaging with magnetic resonance by the use of the intravascular contrast agent Clariscan (NC100150 injection) in patients with coronary artery disease. J Magn Reson Imaging 2003; 17: 656-662. (Pubitemid 36665869)
8. Knuesel PR, Nanz D, Wolfensberger U, et al. Multislice breath-hold spiral magnetic resonance coronary angiography in patients with coronary artery disease: effect of intravascular contrast medium. J Magn Reson Imaging 2002; 16: 660-667. (Pubitemid 35375564)
9. Sandstede JJ, Pabst T, Wacker C, et al. Breath-hold 3D MR coronary angiography with a new intravascular contrast agent (feruglose)-first clinical experiences. Magn Reson Imaging 2001; 19: 201-205. (Pubitemid 32476174)
10. Li D, Zheng J, Weinmann HJ,. Contrast-enhanced MR imaging of coronary arteries: comparison of intra- and extravascular contrast agents in swine. Radiology 2001; 218: 670-678. (Pubitemid 32172546)
11. Schnorr J, Wagner S, Ebert W, et al. [MR angiography of the coronary arteries: comparison of the blood pool contrast medium Gadomer and Gd-DTPA in pigs]. Rofo 2003; 175: 822-829. (Pubitemid 36806766)
12. Taupitz M, Schnorr J, Abramjuk C, et al. New generation of monomer-stabilized very small superparamagnetic iron oxide particles (VSOP) as contrast medium for MR angiography: preclinical results in rats and rabbits. J Magn Reson Imaging 2000; 12: 905-911.
13. Wagner S, Schnorr J, Pilgrimm H, Hamm B, Taupitz M,. Monomer-coated very small superparamagnetic iron oxide particles as contrast medium for magnetic resonance imaging: preclinical in vivo characterization. Invest Radiol 2002; 37: 167-177. (Pubitemid 34259726)
14. Kellar KE, Fujii DK, Gunther WH, Briley-Saebo K, Spiller M, Koenig SH,. 'NC100150', a preparation of iron oxide nanoparticles ideal for positive-contrast MR angiography. MAGMA 1999; 8: 207-213. (Pubitemid 29436574)
15. Li W, Tutton S, Vu AT, et al. First-pass contrast-enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)-based blood pool agent. J Magn Reson Imaging 2005; 21: 46-52. (Pubitemid 40041419)
16. McLachlan SJ, Morris MR, Lucas MA, et al. Phase I clinical evaluation of a new iron oxide MR contrast agent. J Magn Reson Imaging 1994; 4: 301-307.
17. Tombach B, Reimer P, Mahler M, Ebert W, Pering C, Heindel W,. First-pass and equilibrium phase MRA following intravenous bolus injection of SH U 555 C: phase I clinical trial in elderly volunteers with risk factors for arterial vascular disease. Acad Radiol 2002; 9 (Suppl 2): 425-427.
18. Taupitz M, Wagner S, Schnorr J, et al. Phase I clinical evaluation of citrate-coated monocrystalline very small superparamagnetic iron oxide particles as a new contrast medium for magnetic resonance imaging. Invest Radiol 2004; 39: 394-405. (Pubitemid 38802814)
19. Allkemper T, Bremer C, Matuszewski L, Ebert W, Reimer P,. Contrast-enhanced blood-pool MR angiography with optimized iron oxides: effect of size and dose on vascular contrast enhancement in rabbits. Radiology 2002; 223: 432-438. (Pubitemid 34454322)
20. Schnorr J, Wagner S, Abramjuk C, et al. Comparison of the iron oxide-based blood-pool contrast medium VSOP-C184 with gadopentetate dimeglumine for first-pass magnetic resonance angiography of the aorta and renal arteries in pigs. Invest Radiol 2004; 39: 546-553. (Pubitemid 39096772)
21. Taupitz M, Schnorr J, Wagner S, et al. Coronary MR angiography: experimental results with a monomer-stabilized blood pool contrast medium. Radiology 2002; 222: 120-126. (Pubitemid 34031476)
22. Warmuth C, Schnorr J, Kaufels N, et al. Whole-heart coronary magnetic resonance angiography: contrast-enhanced high-resolution, time-resolved 3D imaging. Invest Radiol 2007; 42: 550-557. (Pubitemid 47051831)
23. Pilgrimm H,. Superparamagnetic particles with increased R1 relaxivity, process for producing said particles and use thereof. Patent EP 888545, JP 2000-507197 (2000).
24. Austen WG, Edwards JE, Frye RL, et al. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation 1975; 51: 5-40.
25. Dirksen MS, Lamb HJ, van der Geest R, de Roos A,. Toward comparability of coronary magnetic resonance angiography: proposal for a standardized quantitative assessment. Eur Radiol 2003; 13: 2353-2357. (Pubitemid 37220371)
26. Yang Q, Li K, Liu X, et al. Contrast-enhanced whole-heart coronary magnetic resonance angiography at 3.0-T: a comparative study with X-ray angiography in a single center. J Am Coll Cardiol 2009; 54: 69-76.
27. Taupitz M, Schmitz S, Hamm B, [Superparamagnetic iron oxide particles: current state and future development]. Rofo 2003; 175: 752-765. (Pubitemid 36806756)
28. Huber ME, Paetsch I, Schnackenburg B, et al. Performance of a new gadolinium-based intravascular contrast agent in free-breathing inversion-recovery 3D coronary MRA. Magn Reson Med 2003; 49: 115-121. (Pubitemid 36042340)
29. Paetsch I, Jahnke C, Barkhausen J, et al. Detection of coronary stenoses with contrast enhanced, three-dimensional free breathing coronary MR angiography using the gadolinium-based intravascular contrast agent gadocoletic acid (B-22956). J Cardiovasc Magn Reson 2006; 8: 509-516.
30. Schuetz GM, Zacharopoulou NM, Schlattmann P, Dewey M,. Meta-analysis: noninvasive coronary angiography using computed tomography versus magnetic resonance imaging. Ann Intern Med 2010; 152: 167-177.
31. Schuijf JD, Bax JJ, Shaw LJ, et al. Meta-analysis of comparative diagnostic performance of magnetic resonance imaging and multislice computed tomography for noninvasive coronary angiography. Am Heart J 2006; 151: 404-411. (Pubitemid 43144743)
32. Ruehm SG, Corot C, Vogt P, Kolb S, Debatin JF,. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation 2001; 103: 415-422. (Pubitemid 32105982)
33. Schmitz SA, Coupland SE, Gust R, et al. Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits. Invest Radiol 2000; 35: 460-471. (Pubitemid 30622013)
34. Schmitz SA, Taupitz M, Wagner S, et al. Iron-oxide-enhanced magnetic resonance imaging of atherosclerotic plaques: postmortem analysis of accuracy, inter-observer agreement, and pitfalls. Invest Radiol 2002; 37: 405-411. (Pubitemid 34680203)